What is it about?
Perspectives from both payers and pharmaceutical developers on how they each view and use real-world data to develop real-world evidence and how that evidence might be used for informing drug coverage decisions made by payers.
Featured Image
Why is it important?
Payers and pharmaceutical developers have differing perspectives on real-world evidence; they have different regulatory constraints, and different incentives. This paper explores many of the practical challenges and opportunities for using RWE.
Perspectives
Many have detailed the hopes and shortcomings of RWE, but this paper provides a good summary of the differing perspectives of payers and pharmaceutical developers from a practical perspective.
William Dreitlein
Institute for Clinical and Economic Review
Read the Original
This page is a summary of: Real-world evidence for coverage decisions: opportunities and challenges, Journal of Comparative Effectiveness Research, December 2018, Future Medicine,
DOI: 10.2217/cer-2018-0066.
You can read the full text:
Contributors
The following have contributed to this page
